# Somatropin Peptide

> Somatropin is recombinant human growth hormone that replaces GH signaling, raises IGF-1 activity, and supports growth, metabolism, and tissue maintenance.

Canonical: https://pepflow.app/peptides/somatropin/

The GH Standard

Somatropin is recombinant human growth hormone, a 191-amino-acid pituitary hormone manufactured as prescription injectable products.

GH therapy  Muscle repair  Recovery support

Tier S

Evidence Strong

Safety Well-Studied

FDA status Approved

Last reviewed October 25, 2026 50 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is Somatropin?

Somatropin is recombinant human growth hormone, a 191-amino-acid pituitary hormone manufactured as prescription injectable products.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

It has FDA-approved indications such as growth hormone deficiency and selected pediatric growth or wasting contexts, depending on product label.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

That approved-drug evidence does not generalize to anti-aging, bodybuilding, recovery, or performance protocols, which carry different benefit-risk and anti-doping issues.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) For more context, read the [recombinant human growth hormone explainer](<https://pepflow.app/blog/human-growth-hormone-recombinant/>).

## What Somatropin is investigated for

Somatropin evidence is grouped by practical use case and injectable, intranasal, inhaled, oral, transdermal, and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Pediatric growth hormone deficiency and short-stature disorders Injectable 90% Strong

Pediatric growth-disorder treatment has high-confidence, clinician-managed evidence.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/31514194/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11095419/>)

#### Human evidence

FDA labeling and pediatric endocrine guidelines support somatropin for pediatric growth hormone deficiency and selected short-stature disorders.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/31514194/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11095419/>)

#### Animal / mechanistic evidence

The mechanism is GH receptor and IGF-1 axis replacement in true deficiency or approved pediatric growth-disorder contexts.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/31514194/>) [\[7\]](<https://pubmed.ncbi.nlm.nih.gov/11095419/>)

### ### Adult growth hormone deficiency Injectable 82% Strong

Adult GH deficiency should be its own high-confidence indication rather than hidden inside pediatric growth claims.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/31234055/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/27118206/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/17077947/>)

#### Human evidence

FDA labeling and adult GH deficiency literature support replacement therapy for diagnosed adult GH deficiency.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/31234055/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/27118206/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/17077947/>)

#### Animal / mechanistic evidence

The rationale is physiologic replacement and IGF-1 monitoring, not supraphysiologic enhancement.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[10\]](<https://pubmed.ncbi.nlm.nih.gov/31234055/>) [\[12\]](<https://pubmed.ncbi.nlm.nih.gov/27118206/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/17077947/>)

### ### Lean mass, fat loss, aging, and performance use in healthy adults Injectable 56% Emerging

Lean-mass, fat-loss, and anti-aging claims remain lower confidence and clearly off-label for healthy adults.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/27118206/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/17077947/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[20\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

#### Human evidence

Adult GH studies show fat-mass and lean-mass effects in deficiency contexts, but healthy-adult anti-aging and performance use is not an approved indication.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/27118206/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/17077947/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[20\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

#### Animal / mechanistic evidence

The mechanism is anabolic and lipolytic GH/IGF-1 signaling, which also explains adverse-effect and anti-doping concerns.[\[12\]](<https://pubmed.ncbi.nlm.nih.gov/27118206/>) [\[14\]](<https://pubmed.ncbi.nlm.nih.gov/17077947/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[20\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## Evidence snapshot

### Overall confidence

Strong

90%

Somatropin has strong support for approved growth-hormone replacement and selected endocrine indications. Anti-aging and body-composition use has a different risk-benefit profile.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

90%

### Human evidence

Strong

FDA-approved somatropin products have labeled endocrine indications with dose and safety monitoring.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

34%

### Animal / preclinical

Limited

GH receptor and IGF-1 biology directly supports replacement therapy.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

90%

### Mechanism support

Strong

Somatropin binds growth hormone receptors and increases hepatic and local IGF-1 signaling. The axis affects growth, body composition, glucose, fluid balance, and tissue turnover.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

## Forms & administration

Somatropin is supplied as approved injectable medicines, including ready-to-use Norditropin FlexPro pens. Nasal, inhaled and local dental formulations remain investigational. Encapsulated oral and microneedle preparations have preclinical support only; their amounts, absorption and preparation cannot be equated with prescription injectable products.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[21\]](<https://pubmed.ncbi.nlm.nih.gov/26425883/>) [\[22\]](<https://pubmed.ncbi.nlm.nih.gov/19549433/>) [\[23\]](<https://pubmed.ncbi.nlm.nih.gov/27742865/>) [\[24\]](<https://pubmed.ncbi.nlm.nih.gov/24838219/>) [\[25\]](<https://pubmed.ncbi.nlm.nih.gov/37113816/>)

Injectable Nasal spray Inhaled Oral Transdermal Topical

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Adult growth hormone deficiency usually starts at 0.15-0.30 mg per day. A common starting dose is 0.2 mg.[\[27\]](<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5>)

### Frequency

Usually taken once daily.[\[27\]](<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5>)

### Timing Considerations

Evening is the usual timing.[\[27\]](<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5>)

### Cycle Length

Treatment is ongoing and adjusted over time.[\[27\]](<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5>)

[Full Somatropin dosage guide](<https://pepflow.app/peptides/somatropin/dosage/>)

## What to expect

### First weeks

Injectable somatropin replacement may feel like shifts in energy, sleep, body-fluid balance, or adult GH-deficiency symptoms.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>)

### Months

Injectable treatment outcomes unfold through pediatric growth velocity or adult body composition, symptoms, IGF-1, and metabolic labs.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>)

### After stopping

Hormone-axis effects drift toward baseline after injectable somatropin stops unless the underlying deficiency is treated another way.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>)

## Safety profile

Somatropin has prescription-label safety concerns around glucose, fluid retention, joint symptoms, malignancy, intracranial pressure, retinopathy, and pediatric indication limits.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

### Common side effects

- Fluid retention [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- Joint discomfort [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- Muscle pain [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- Glucose changes [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

### Cautions

- Active malignancy[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- Acute critical illness[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- Diabetes / retinopathy[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- Intracranial pressure[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

### What we don't know

Anti-aging, bodybuilding, and other non-replacement uses have a different risk-benefit profile from approved somatropin therapy.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

## Who Somatropin is not for

Route-specific avoid and medical-review notes:

- **Active malignancy**

  Active malignancy warrants medical review or avoidance for Somatropin.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- **Acute critical illness per label**

  Acute critical illness per label use warrants medical review or avoidance for Somatropin.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- **Pregnancy or breastfeeding without clinician review**

  Pregnancy or breastfeeding without clinician review warrants medical review or avoidance for Somatropin.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Documented interactions

- **Glucocorticoids**

  The Norditropin label states somatropin can reduce cortisol concentrations and glucocorticoid replacement doses may require adjustment.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- **CYP450-metabolized drugs**

  The Norditropin label says somatropin may alter clearance of drugs metabolized by CP450 liver enzymes.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- **Oral estrogen**

  The Norditropin label states oral estrogens may reduce IGF-1 response and higher somatropin doses may be required.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- **Insulin / hypoglycemic agents**

  The Norditropin label states somatropin may decrease insulin sensitivity and diabetes medications may require dose adjustment.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

### Theoretical interactions

- **GH secretagogues**

  Ipamorelin, GHRPs, sermorelin, or IGF products can stack GH/IGF exposure, edema, and glucose effects; this is a GH/insulin-axis caution.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- **Anabolic hormones**

  Testosterone or anabolic agents can compound edema, sleep-apnea, and growth-signal tracking; this is a theoretical pathway caution.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)

## Pairing notes

### Not recommended with

**Tesamorelin: compounded GH/IGF-1 effects** Injectable

Somatropin supplies growth hormone directly, while tesamorelin increases the body's own growth-hormone release. Using both can compound GH/IGF-1, fluid-retention, and glucose effects.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**CJC-1295: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[40\]](<https://pubmed.ncbi.nlm.nih.gov/16352683/>) [\[41\]](<https://www.fda.gov/media/183819/download>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**CJC-1295 No DAC: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[42\]](<https://pubmed.ncbi.nlm.nih.gov/2866496/>) [\[31\]](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**Sermorelin: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[43\]](<https://pubmed.ncbi.nlm.nih.gov/8772599/>) [\[44\]](<https://www.fda.gov/media/94155/download>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**Ipamorelin: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[45\]](<https://pubmed.ncbi.nlm.nih.gov/10496658/>) [\[46\]](<https://www.fda.gov/media/182088/download>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**GHRP-2: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[47\]](<https://pubmed.ncbi.nlm.nih.gov/10037246/>) [\[48\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**GHRP-6: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[49\]](<https://pubmed.ncbi.nlm.nih.gov/7952160/>) [\[48\]](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

**Hexarelin: added GH-axis stimulation** Injectable

This pairing compounds GH/IGF-1 stimulation through direct growth hormone plus an upstream release signal, increasing the need to review IGF-1, glucose, fluid retention, joint symptoms, and the reason for using both.[\[50\]](<https://pubmed.ncbi.nlm.nih.gov/8921821/>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

## Regulatory status

### United States

In the U.S. as of 2026-06-21, somatropin injection has FDA-approved product labels for specific growth hormone indications. Anti-aging, bodybuilding, and casual wellness use are not approved indications, and compounded products are separate from the labels.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[29\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Injectable | Approved · FDA-approved somatropin injection products exist for labeled growth hormone deficiency and related indications; anti-aging, bodybuilding, or wellness use is outside those labels.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) | Not Listed · 503A compounding for Somatropin is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[29\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[30\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>) |

### Injectable

FDA drug approval

Approved

FDA-approved somatropin injection products exist for labeled growth hormone deficiency and related indications; anti-aging, bodybuilding, or wellness use is outside those labels.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>)

503A compounding

Not Listed

503A compounding for Somatropin is separate from FDA-approved product labeling; a compounded preparation is not the approved product and is not FDA-approved.[\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[29\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[30\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

### International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. A U.S. FDA approval does not automatically establish the same approved indication, route, or product status in those markets.[\[32\]](<https://www.ema.europa.eu/en/medicines>) [\[33\]](<https://products.mhra.gov.uk/>) [\[34\]](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>) [\[35\]](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)

### Sports & competition

WADA S2 prohibits growth hormone; tested athletes should not use somatropin unless a valid TUE and sport-specific anti-doping review apply.[\[20\]](<https://ita.sport/resource/wada-2026-prohibited-list/>) [\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[29\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>) [\[30\]](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)

## How it works

Somatropin binds growth hormone receptors and increases hepatic and local IGF-1 signaling. In plain terms, it replaces or augments a hormone axis that affects linear growth, body composition, glucose handling, water retention, and tissue turnover.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

Injectable prescription use is inseparable from monitoring. The same GH/IGF-1 pathway explains glucose intolerance, edema, joint symptoms, intracranial-pressure symptoms, neoplasm-history review, and pediatric growth-plate status, so wellness or bodybuilding extrapolations are not route-labeled medicine. The route is medical only when paired with diagnosis and follow-up.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

## Research gaps & open questions

What the current literature has not yet settled about Somatropin:

01

Trials in adults without growth-hormone deficiency still need to show whether anti-aging use provides meaningful benefits that outweigh risks such as swelling, joint pain, blood-sugar problems, and abnormal tissue growth.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

02

Long-term safety is not established for healthy or non-deficient users, especially with repeated or high-dose exposure.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

03

It is not clear how off-label users can be monitored safely outside endocrine care, including which symptoms or changes in IGF-1, blood sugar, and thyroid function should trigger a dose change or stop.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

## Common questions

### Is somatropin HGH?

Yes. Somatropin is recombinant human growth hormone, an injectable prescription product used for specific labeled growth hormone indications.[\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>)

### Is somatropin FDA-approved?

Yes. Somatropin injection products are FDA-approved in the U.S. for specific labeled growth hormone indications.[\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>)

### Is HGH approved for anti-aging?

No. HGH is not FDA-approved for anti-aging or performance use; those outcomes are separate from approved somatropin indications.[\[18\]](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>) [\[19\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>)

## Myths & misconceptions

### Myth

HGH is just a recovery peptide.

### Reality

It is a systemic hormone with glucose, fluid, cancer-history, and endocrine monitoring issues.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

### Myth

FDA approval makes any HGH use legitimate.

### Reality

Approval is indication-, product-, and route-specific.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

## History & discovery

Somatropin replaced earlier pituitary-derived growth hormone with recombinant human growth hormone products that could be manufactured consistently. Its history is prescription endocrinology, not generic wellness. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

Recombinant somatropin became established for specific pediatric and adult growth-hormone indications. That history tied dosing to diagnosis, monitoring, and product labeling.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

Clinical guidelines separated supported growth-hormone uses from weaker or off-label claims. Anti-aging and performance markets grew anyway, making safety and legality central to modern interpretation.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/27884013/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/28525404/>) [\[3\]](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)

## Published research 50 citations

- [\[1\] **Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency.** Horm Res Paediatr, 2016. review.](<https://pubmed.ncbi.nlm.nih.gov/27884013/>)
- [\[2\] **Growth hormone treatment for growth hormone deficiency and idiopathic short stature: new guidelines shaped by the presence and absence of evidence.** Curr Opin Pediatr, 2017 Aug. review.](<https://pubmed.ncbi.nlm.nih.gov/28525404/>)
- [\[3\] **NORDITROPIN somatropin injection prescribing information** U.S. Food and Drug Administration. official guidance.](<https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021148s062lbl.pdf>)
- [\[4\] **Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline.** Eur J Endocrinol, 2022 Apr 21. review.](<https://pubmed.ncbi.nlm.nih.gov/35353710/>)
- [\[5\] **Diagnosis, Genetics, and Therapy of Short Stature in Children: A Growth Hormone Research Society International Perspective.** Horm Res Paediatr, 2019. review.](<https://pubmed.ncbi.nlm.nih.gov/31514194/>)
- [\[6\] **Growth hormone therapy and treatment outcomes: current clinical practice of the Gulf Cooperation Council.** Expert Rev Endocrinol Metab, 2014 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/30763992/>)
- [\[7\] **Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society.** J Clin Endocrinol Metab, 2000 Nov. review.](<https://pubmed.ncbi.nlm.nih.gov/11095419/>)
- [\[8\] **Consensus and controversies about diagnosing GH deficiency: a Delphi survey by the GH research society.** Pituitary, 2025 May 7. review.](<https://pubmed.ncbi.nlm.nih.gov/40335774/>)
- [\[9\] **A review of guidelines for use of growth hormone in pediatric and transition patients.** Pituitary, 2012 Sep. review.](<https://pubmed.ncbi.nlm.nih.gov/22271255/>)
- [\[10\] **Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway.** Growth Horm IGF Res, 2019 Jun-Aug. review.](<https://pubmed.ncbi.nlm.nih.gov/31234055/>)
- [\[11\] **Isolated growth hormone deficiency in children and adolescents.** J Pediatr Endocrinol Metab, 2001 Jul. review.](<https://pubmed.ncbi.nlm.nih.gov/11529396/>)
- [\[12\] **Comparison of low-normal and high-normal IGF-1 target levels during growth hormone replacement therapy: A randomized clinical trial in adult growth hormone deficiency.** Eur J Intern Med, 2016 Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/27118206/>)
- [\[13\] **Controversies in the diagnosis and management of growth hormone deficiency in childhood and adolescence.** Arch Dis Child, 2016 Jan. review.](<https://pubmed.ncbi.nlm.nih.gov/26153506/>)
- [\[14\] **Growth hormone deficiency in the adult.** Pituitary, 2006. review.](<https://pubmed.ncbi.nlm.nih.gov/17077947/>)
- [\[15\] **Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood.** Pituitary, 2007. review.](<https://pubmed.ncbi.nlm.nih.gov/17429591/>)
- [\[16\] **Diagnosis and management of congenital hypopituitarism in children.** Arch Pediatr, 2024 Apr. review.](<https://pubmed.ncbi.nlm.nih.gov/38538470/>)
- [\[17\] **\[Growth hormone treatment update\].** Arch Argent Pediatr, 2014 Feb. review.](<https://pubmed.ncbi.nlm.nih.gov/24566789/>)
- [\[18\] **Drugs@FDA/openFDA query for Somatropin** U.S. Food and Drug Administration. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%22Somatropin%22&limit=1>)
- [\[19\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[20\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)
- [\[21\] **Intranasal Human Growth Hormone Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.** Journal of Clinical Endocrinology & Metabolism, 2015. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/26425883/>)
- [\[22\] **Short-term safety of somatropin inhalation powder in adults with mild to moderate asthma.** Allergy and asthma proceedings, 2009 May-Jun. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/19549433/>)
- [\[23\] **Oral delivery of human growth hormone: Preparation, characterization, and pharmacokinetics.** Journal of biomaterials applications, 2017 Jan. animal.](<https://pubmed.ncbi.nlm.nih.gov/27742865/>)
- [\[24\] **Human Growth Hormone Delivery with a Microneedle Transdermal System: Preclinical Formulation, Stability, Delivery and PK of Therapeutically Relevant Doses.** Pharmaceutics, 2014 May 15. animal.](<https://pubmed.ncbi.nlm.nih.gov/24838219/>)
- [\[25\] **Evaluation of human growth hormone (somatropin) in socket healing: a split-mouth randomized controlled trial.** Annals of medicine and surgery (2012), 2023 Apr. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/37113816/>)
- [\[26\] **Bioavailability and bioactivity of three different doses of nasal growth hormone administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.** Eur J Endocrinol, 1996 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8890721/>)
- [\[27\] **OMNITROPE somatropin prescribing information** U.S. Food and Drug Administration via DailyMed. official guidance.](<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=58d84ffa-4056-4e36-ad67-7bd4aef444a5>)
- [\[28\] **FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/cosmetics/cosmetics-laws-regulations/fda-authority-over-cosmetics-how-cosmetics-are-not-fda-approved-are-fda-regulated>)
- [\[29\] **Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act>)
- [\[30\] **Bulk Drug Substances Used in Compounding Under Section 503B of the FD&C Act** U.S. Food and Drug Administration, 2025-01-07. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503b-fdc-act>)
- [\[31\] **Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks** U.S. Food and Drug Administration, 2026-04-22. regulatory.](<https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks>)
- [\[32\] **European Medicines Agency medicines search** European Medicines Agency. official guidance.](<https://www.ema.europa.eu/en/medicines>)
- [\[33\] **MHRA Products search** Medicines and Healthcare products Regulatory Agency. official guidance.](<https://products.mhra.gov.uk/>)
- [\[34\] **Drug Product Database: Access the database** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>)
- [\[35\] **Searching the Australian Register of Therapeutic Goods** Therapeutic Goods Administration. official guidance.](<https://www.tga.gov.au/products/regulations-all-products/about-australian-register-therapeutic-goods-artg/searching-australian-register-therapeutic-goods-artg>)
- [\[36\] **Cosmetic Products Regulation** European Commission. official guidance.](<https://single-market-economy.ec.europa.eu/sectors/cosmetics/legislation_en>)
- [\[37\] **Making cosmetic products available to consumers in Great Britain** UK Office for Product Safety and Standards. official guidance.](<https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain>)
- [\[38\] **Cosmetics regulatory information** Health Canada. official guidance.](<https://www.canada.ca/en/health-canada/services/consumer-product-safety/cosmetics/regulatory-information.html>)
- [\[39\] **Cosmetics and soap** Australian Industrial Chemicals Introduction Scheme. official guidance.](<https://www.industrialchemicals.gov.au/cosmetics-and-soap>)
- [\[40\] **Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.** PubMed / Journal of Clinical Endocrinology and Metabolism, 2006. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/16352683/>)
- [\[41\] **FDA Evaluation of CJC-1295 Related Bulk Drug Substances for the December 4, 2024 Pharmacy Compounding Advisory Committee Meeting** U.S. Food and Drug Administration, 2024. regulatory.](<https://www.fda.gov/media/183819/download>)
- [\[42\] **Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men.** PubMed / Peptides, 1985. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/2866496/>)
- [\[43\] **Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.** The Journal of clinical endocrinology and metabolism, 1996 Mar. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8772599/>)
- [\[44\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[45\] **Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.** Pharmaceutical research, 1999 Sep. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/10496658/>)
- [\[46\] **October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee - FDA Briefing Document 4 - Ipamorelin** U.S. Food and Drug Administration, 2024-10-29. regulatory.](<https://www.fda.gov/media/182088/download>)
- [\[47\] **Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.** European journal of endocrinology, 1999 Jan. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/10037246/>)
- [\[48\] **United Pharmacy MARCS-CMS 553916 - February 11, 2019** U.S. Food and Drug Administration, 2019-02-11. regulatory.](<https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/united-pharmacy-553916-02112019>)
- [\[49\] **Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging** European Journal of Endocrinology, 1994-11. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/7952160/>)
- [\[50\] **Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging.** European Journal of Endocrinology, 1996 Oct. human clinical.](<https://pubmed.ncbi.nlm.nih.gov/8921821/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

GH/IGF axis peptide

**Tier**

S

**Evidence**

90% Strong

**Safety**

Well-Studied

**FDA status**

Approved

**Injectable 503A**

Not Listed

**Citations**

[50 citations](<https://pepflow.app/peptides/somatropin/#published-research>)

**Updated**

October 25, 2026

### Potential benefits

- Pediatric growth hormone deficiency and short-stature disorders
- Adult growth hormone deficiency
- Lean mass, fat loss, aging, and performance use in healthy adults

### Common side effects

- Fluid retention
- Joint discomfort
- Muscle pain

### Also known as

- Recombinant human growth hormone
- rhGH
- Human growth hormone
- HGH

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [Human Growth Hormone Recombinant: 2026 Guide](<https://pepflow.app/blog/human-growth-hormone-recombinant/>)
- [Somatropin dosage guide](<https://pepflow.app/peptides/somatropin/dosage/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
